RGC (Regencell Bioscience Holdings) Other Long-Term Liabilities: $1.79 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGC Regencell Bioscience Holdings Ltd RGC
30 GF Score
Price $5.41
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings Other Long-Term Liabilities?

Regencell Bioscience Holdings RGC -0.55% 30 Other Long-Term Liabilities is $1.79 Mil as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Regencell Bioscience Holdings's other long-term liabilities for the quarter that ended in Dec. 2025 was $1.79 Mil.

Regencell Bioscience Holdings's quarterly other long-term liabilities declined from Dec. 2024 ($0.76 Mil) to Jun. 2025 ($-0.00 Mil) but then increased from Jun. 2025 ($-0.00 Mil) to Dec. 2025 ($1.79 Mil).

Regencell Bioscience Holdings's annual other long-term liabilities declined from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil) and declined from Jun. 2024 ($-0.00 Mil) to Jun. 2025 ($-0.00 Mil).

Regencell Bioscience Holdings Other Long-Term Liabilities Related Terms

Regencell Bioscience Holdings Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings Other Long-Term Liabilities Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 -0.00 -0.00

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 -0.00 0.76 -0.00 1.79
RGC
30GF Score
Regencell Bioscience Holdings Ltd RGC
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $1.79 Mil mean?
Regencell Bioscience Holdings (RGC) has a Other Long-Term Liabilities of $1.79 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regencell Bioscience Holdings and its competitors.
Is Regencell Bioscience Holdings' Other Long-Term Liabilities too high?
Regencell Bioscience Holdings' current Other Long-Term Liabilities is $1.79 Mil. Overall, Regencell Bioscience Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Other Long-Term Liabilities compare to SUPN and BCRX?
Regencell Bioscience Holdings' Other Long-Term Liabilities of $1.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regencell Bioscience Holdings and its competitors. Regencell Bioscience Holdings's current Other Long-Term Liabilities is $1.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Other Long-Term Liabilities of $1.79 Mil. The current Other Long-Term Liabilities is $1.79 Mil. Regencell Bioscience Holdings' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Other Long-Term Liabilities is $1.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
30GF Score

Get the complete analysis for RGC

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.41
Price